Info

Acadia Pharmaceuticals Inc. (Acadia Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company has six programs in clinical development and several additional programs in development and discovery stages. In its advanced program, the Company is entering Phase III development with pimavanserin for the treatment of Parkinson’s disease psychosis. It has results from a Phase II trial in its program with pimavanserin as a co-therapy in schizophrenia. It also has completed enrollment of a Phase IIb trial in its program with ACP-104 as a treatment for schizophrenia. The Company has completed a clinical trial with pimavanserin for the treatment of sleep maintenance insomnia in healthy older adults. In addition, it has a neuropathic pain program in Phase II clinical trials and a glaucoma program in Phase I trial in collaboration with Allergan, Inc.(Source: 10-K)